RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Very difficult to be constructiveThey said that they tested many patients with multiple doses at 420 mg/m2 and these patients were likely treated at 300 mg/m2 before that. I understand phase Ia is not designed to show efficacy in the best possible way, that being said, given they know which cancer are very likely to overexpress sortilin, it is hard to believe that out of all that not a single patient will show some tumor shrinkage. If the concept behind TH1902 is valid, there has to be at least one or two patients showing some signs of efficacy. Likely it will not be the full efficacy of the drug given at the right dose for 6 cycles or more, but at least there has to be some signs. If there is absolutely no signs of efficacy in any patients, it will be very worrisome.
jeffm34 wrote: What results are you expecting from the the phase 1a? The only results they will announce will be the dose they are using in the phase 1b trial. They've already said that will be 300mg barring any major change in findings.
SPCEO1 wrote: Obviously, the timing is hard too as we should be hearing about the phase 1a results right around the time of the AGM